Is semaglutide safe to continue in a 57-year-old woman with hormone-receptor-positive breast cancer undergoing chemotherapy and radiation?

Semaglutide During Chemotherapy and Radiation for Hormone-Positive Breast Cancer

Semaglutide can be continued during chemotherapy and radiation for hormone-positive breast cancer, but requires close monitoring for nutrition, body composition, and treatment tolerance, with particular attention to delayed gastric emptying and potential peri-procedural aspiration risk.

Key Safety Considerations

Cancer-Specific Safety Profile

The FDA label for semaglutide does not list breast cancer as a contraindication, and recent systematic reviews show no increased risk of any cancer type, including breast cancer 1. In fact, emerging preclinical data suggests semaglutide may enhance antitumor immunity in breast cancer models 2. A comprehensive meta-analysis of 37 RCTs involving over 46,000 patients found no increased occurrence of any malignancies with semaglutide compared to placebo or active controls 1.

Critical Peri-Treatment Concerns

Body Composition and Treatment Tolerance: The most significant concern during active cancer therapy is that GLP-1 receptor agonists cause weight loss that includes 20-30% lean muscle mass 3. In oncology, low skeletal muscle mass correlates with higher rates of severe toxicity, more dose modifications, and worse survival 3. This patient requires systematic body composition monitoring (not just weight), dietetic support, and resistance exercise programming if continuing semaglutide during chemotherapy and radiation 3.

Delayed Gastric Emptying: Semaglutide delays gastric emptying, which has two implications:

• Peri-procedural aspiration risk: Multiple case reports document regurgitation and pulmonary aspiration during anesthesia in patients on GLP-1 receptor agonists, even with prolonged fasting (>12-20 hours) 4. For any procedures requiring anesthesia during treatment, consider holding semaglutide for at least 1 week (given its ~1 week half-life 5) and ensure anesthesia teams are aware.
• Oral medication absorption: Delayed gastric emptying may alter the pharmacokinetics of oral chemotherapy agents or supportive medications, though overall drug exposure is typically preserved 3.

Gastrointestinal and Metabolic Monitoring

Common side effects include nausea, vomiting, and diarrhea 5, which can compound chemotherapy-induced gastrointestinal toxicity. One case report documented multi-organ complications (gastroparesis, cholecystitis, colitis, acute kidney injury from dehydration) visible on PET/CT after a single semaglutide dose in a patient with metastatic breast cancer 6.

Monitor for:

• Dehydration and electrolyte abnormalities
• Gallbladder disease (cholelithiasis risk is established 7)
• Adequate caloric and protein intake to preserve lean mass

Rare but Serious Adverse Events

While extremely rare, one case report documented agranulocytosis requiring G-CSF in a patient on semaglutide 8. During chemotherapy when neutropenia is expected, baseline and serial complete blood counts are already standard practice, but awareness of this potential drug effect is warranted.

Practical Management Algorithm

1. Baseline Assessment:

   • Body composition analysis (DEXA or CT-based sarcopenia assessment)
   • Nutritional status evaluation
   • Review of planned chemotherapy regimen and procedural schedule

2. During Treatment:

   • Monthly body composition monitoring (not just weight)
   • Dietitian consultation with protein intake goal ≥1.2 g/kg/day
   • Resistance exercise prescription (2-3x/week if tolerated)
   • Monitor for gastrointestinal symptoms requiring dose adjustment

3. Peri-Procedural Management:

   • Hold semaglutide ≥1 week before any procedure requiring anesthesia
   • Inform anesthesia team of GLP-1 receptor agonist use
   • Consider point-of-care gastric ultrasound if available

4. Consider Temporary Discontinuation If:

   • Significant lean mass loss (>5% skeletal muscle in 3 months)
   • Severe chemotherapy-induced nausea/vomiting compounded by semaglutide
   • Inability to maintain adequate nutrition
   • Frequent procedures requiring anesthesia

Hormone Therapy Considerations

The provided guidelines focus on endocrine therapy for hormone-positive breast cancer 9, 10 but do not address GLP-1 receptor agonist interactions. There are no known pharmacokinetic interactions between semaglutide and aromatase inhibitors or tamoxifen. However, maintaining adequate nutrition and body composition is critical for treatment completion, as older age and lower body mass index predict hormone therapy discontinuation 11.

Bottom Line

Continue semaglutide with intensive supportive care monitoring, or consider temporary discontinuation during the most intensive treatment phases (chemotherapy) with resumption after completion. The decision should weigh the cardiometabolic benefits of semaglutide against the risks of sarcopenia-related treatment intolerance. For this 57-year-old woman, if she has significant cardiometabolic indications for semaglutide (diabetes, cardiovascular disease), continuation with close monitoring is reasonable. If prescribed primarily for weight management, temporary discontinuation during chemotherapy may be prudent to optimize treatment tolerance and preserve lean mass.